Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease (2017)
- Authors:
- Lincoff, A. Michael
- Nicholls, Stephen J.
- Riesmeyer, Jeffrey S.
- Barter, Philip J.
- Brewer, H. Bryan
- Fox, Keith A.A.
- Gibson, C. Michael
- Granger, Christopher
- Menon, Venu
- Montalescot, Gilles
- Rader, Daniel
- Tall, Alan R.
- McErlean, Ellen
- Wolski, Kathy
- Ruotolo, Giacomo
- Vangerow, Burkhard
- Weerakkody, Govinda
- Goodman, Shaun G.
- Conde, Diego
- McGuire, Darren K.
- Nicolau, Jose C.
- Leiva-Pons, Jose L.
- Pesant, Yves
- Li, Weimin
- Kandath, David
- Kouz, Simon
- Tahirkheli, Naeem
- Mason, Denise
- Nissen, Steven E.
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1056/NEJMoa1609581
- Subjects: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; COLESTEROL; DOENÇAS CARDIOVASCULARES; ESTUDOS RANDOMIZADOS
- Language: Inglês
- Imprenta:
- Source:
- Título: The New England Journal of Medicine
- ISSN: 0028-4793
- Volume/Número/Paginação/Ano: v. 376, n. 20, p. 1933-1942, 2017
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
LINCOFF, A. Michael et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. The New England Journal of Medicine, v. 376, n. 20, p. 1933-1942, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581. Acesso em: 05 mar. 2026. -
APA
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., et al. (2017). Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. The New England Journal of Medicine, 376( 20), 1933-1942. doi:10.1056/NEJMoa1609581 -
NLM
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease [Internet]. The New England Journal of Medicine. 2017 ; 376( 20): 1933-1942.[citado 2026 mar. 05 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581 -
Vancouver
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease [Internet]. The New England Journal of Medicine. 2017 ; 376( 20): 1933-1942.[citado 2026 mar. 05 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1609581 - Sex difference in patients with ischemic heart failure undergoing surgical revascularization results from the STICH trial (Surgical Treatment for Ischemic Heart Failure)
- Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial
- Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI-38 Coronary Stent Registry
- Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial
- Aneurisma Verdadeiro Gigante e Calcificado do Ventrículo Esquerdo: como Proceder?
- Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF
- Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
- Comparison between two different local hemostatic methods for dental extractions in patients on dual antiplatelet therapy: a within-person, single-blind, randomized study
- Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: results of REAL-TIMI 63B
- Predictors of subclinical carotid atherosclerosis in middle-aged women
Informações sobre o DOI: 10.1056/NEJMoa1609581 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
